|
06 Sep 2025 |
Canara Bank
|
Consensus Share Price Target
|
107.14 |
123.69 |
- |
15.45 |
buy
|
|
|
|
|
26 Oct 2021
|
Canara Bank
|
Motilal Oswal
|
107.14
|
270.00
|
200.80
(-46.64%)
|
Target met |
Buy
|
|
|
On the asset quality front, slippages were elevated at ~INR69b (annualised 4.2% of loans), mainly due to a large corporate account, while higher recoveries and upgrades aided an improvement of 8bp/25bp QoQ in the GNPA/NNPA ratio. Further, SMA overdue declined to ~2% of loans (v/s ~3.0% in 1QFY22), while restructured portfolio remained stable QoQ at 2.9% of loans. Overall, we expect CBK's credit costs to moderate from FY23E...
|
|
19 May 2021
|
Canara Bank
|
BOB Capital Markets Ltd.
|
107.14
|
165.00
|
146.40
(-26.82%)
|
Target met |
Accumulate
|
|
|
Canara Bank (CBK) reported Q4FY21 PAT of Rs 10bn aided by 6% QoQ growth in operating profit.
|
|
07 Mar 2021
|
Canara Bank
|
LKP Securities
|
107.14
|
210.00
|
161.20
(-33.54%)
|
Target met |
Buy
|
|
|
|
|
28 Jan 2021
|
Canara Bank
|
BOB Capital Markets Ltd.
|
107.14
|
150.00
|
132.00
(-18.83%)
|
Target met |
Accumulate
|
|
|
Canara Bank's (CBK) Q3 PAT of Rs 7bn beat our estimate on strong 47% YoY growth in operating profit.
|
|
03 Nov 2020
|
Canara Bank
|
Dolat Capital
|
107.14
|
95.00
|
88.60
(20.93%)
|
Target met |
Sell
|
|
|
Canara bank reported better than expected NII and PPoP growth of 29% and 32% YoY respectively on an amalgamated basis, driven by improved spreads, healthy growth in fee income, elevated treasury gains, and high recoveries from w/off accounts. Collection efficiency stood at 92-95% for the month of Sep, including past arrears. Management estimates ~Rs130bn or 2% of loans to be...
|
|
25 Jun 2020
|
Canara Bank
|
BOB Capital Markets Ltd.
|
107.14
|
120.00
|
104.50
(2.53%)
|
Target met |
Accumulate
|
|
|
Canara Bank (CBK) reported a Rs 32.6bn loss as the bank consciously made higher wage and NPA-related provisions due to amalgamation.
|
|
25 Jun 2020
|
Canara Bank
|
Dolat Capital
|
107.14
|
108.00
|
104.50
(2.53%)
|
Target met |
Buy
|
|
|
Sub-par core earnings (PPoP/assets at 1.5%), elevated credit costs, and focus on merger could continue to pressurize earnings over the medium term. We have a REDUCE recommendation on the stock with...
|
|
23 Jan 2020
|
Canara Bank
|
SMC online
|
107.14
|
|
218.80
(-51.03%)
|
Pre-Bonus/ Split |
Buy
|
|
|
supported by Insulin Glargine and good traction in biologics. Disclaimer: This Research Report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to the investor. It is only for private circulation and use. The Research Report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of this Research Report. The Research Report should not be reproduced or redistributed to any other person(s)in any form without prior written permission of the SMC. The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this Research Report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions. Please note that SMC its affiliates, Research Analyst, officers, directors, and employees, including persons involved in the preparation or issuance if this Research Report: (a) from time to time, may have long or short positions in, and buy or sell the securities thereof, of the subject company(ies) mentioned here in; or (b) be engaged in any other transaction involving such securities and earn...
|
|
25 Feb 2019
|
Canara Bank
|
Rudra Shares and Stock Brokers Ltd
|
107.14
|
277.00
|
223.00
(-51.96%)
|
Target met |
Buy
|
|
|
Bank expects Global NIM to reach 2.75% (currently 2.65%) going forward & aims at improving the bottom-line further with balanced thrust on both retail and corporate advances coupled with increased adoption of digitalization for efficiency improvement. Bank intends to continue with the growth in the retail advances while simultaneously focusing on improvement in corporate book with high rated corporate advances. Moreover, management is highly confident...
|
|
29 Jan 2019
|
Canara Bank
|
BOB Capital Markets Ltd.
|
107.14
|
270.00
|
247.60
(-56.73%)
|
Target met |
Buy
|
|
|
Persistent Systems (PSYS) reported below-par Q3FY19 revenues but a beat on margins. Digital business returned to growth after two quarters of QoQ decline. Despite onsite constraints, PSYS benefited from higher billing rates and a better offshore mix, which fueled EBITDA margins (+250bps QoQ). We upgrade the stock from REDUCE to ADD on attractive valuations post a 30% price correction since we initiated coverage in Jul'18. Baking in higher margins,...
|